Mesenchymal Cell News Volume 6.13 | Apr 8 2014

Mesenchymal Stem Cells Prevent Hypertrophic Scar Formation via Inflammatory Regulation When Undergoing Apoptosis
Scientists locally injected human mesenchymal stem cells (hMSCs) derived from bone marrow to treat hypertrophic scar formation, and explored the underlying mechanisms. They found that hMSC therapy efficiently regulated inflammation and prevented scar formation. [J Invest Dermatol] Abstract

Adrenaline Stimulates the Proliferation and Migration of Mesenchymal Stem Cells towards the LPS-Induced Lung Injury
Researchers found that adrenaline at 10 µM enhanced proliferation of bone marrow-derived mesenchymal stem cells (BMSCs) through both a- and ß-adrenergic receptors. Adrenaline promoted the migration of BMSCs towards lipopolysaccharide (LPS)-injured lung cells or lung tissue. [J Cell Mol Med] Full Article

Matrix Composition and Mechanics Directs Pro-Angiogenic Signaling from Mesenchymal Stem Cells
Researchers showed how controlling the mechanical properties and protein composition of the extracellular matrix surrounding mesenchymal stem cells can guide pro-angiogenic signaling. [Tissue Eng Part A] Abstract

Downregulation of HDAC1 Is Involved in the Cardiomyocyte Differentiation from Mesenchymal Stem Cells in a Myocardial Microenvironment
Investigators determined the acetylation regulatory mechanisms that may be involved in the directed cardiomyocyte differentiation from mesenchymal stem cells. [PLoS One] Full Article

Delayed Administration of Bone Marrow Mesenchymal Stem Cell Conditioned Media Significantly Improves Outcome after Retinal Ischemia in Rats
Researchers hypothesized that injection of bone marrow stem cell conditioned media after ischemia could rescue ischemic retina, and in this study they characterized the functional and histological outcomes, and mechanisms of this neuroprotection. [Invest Ophthalmol Vis Sci] Abstract

Artificial Matrices with High-Sulfated Glycosaminoglycans and Collagen Are Anti-Inflammatory and Pro-Osteogenic for Human Mesenchymal Stromal Cells
The influence of artificial extracellular matrices on the interleukin-1ß-induced pro-inflammatory response of human mesenchymal stromal cells was studied. [J Cell Biochem] Abstract

Micro-Aggregates Do Not Influence Bone Marrow Stromal Cell Chondrogenesis
Researchers investigated the role of the cellular environment (paracrine vs juxtacrine signaling) in the chondrogenic differentiation of bone marrow stromal cells. [J Tissue Eng Regen Med] Abstract

Mir-218 Contributes to the Transformation of 5-Aza/GF Induced Umbilical Cord Mesenchymal Stem Cells into Hematopoietic Cells through the MITF Pathway
Scientists demonstrated that umbilical cord-derived human mesenchymal stem cells are easily accessible and could be induced into cells with hematopoietic function. [Mol Biol Rep] Abstract

Human Mesenchymal Stem Cells Express a Myofibroblastic Phenotype In Vitro: Comparison to Human Cardiac Myofibroblasts
Scientists report that, while human bone marrow-derived mesenchymal stem cells retain pluripotency, they adopt a myofibroblastic phenotype in culture and stain positive for the myofibroblast markers a-SMA, vimentin, NMMIIB, ED-A fibronectin, and collagen type 1 at each passage. [Mol Cell Biochem] Abstract

An Update of Human Mesenchymal Stem Cell Biology and Their Clinical Uses
Stromal (mesenchymal) stem cells (MSCs) are being introduced into many clinical trials due to their ease of isolation and efficacy in treating a number of disease conditions in animal preclinical disease models. The aim of this review is to revise MSC biology, their potential translation in therapy, and the challenges facing their adaptation in clinical practice. [Arch Toxicol] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell’s itMSC Therapy to Treat Dilated Chronic Heart Failure
CardioCell LLC has received the FDA’s investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure, which generates more than 1 million hospitalizations annually. [CardioCell LLC] Press Release

TiGenix Licenses Exclusive Marketing and Distribution Rights for ChondroCelect to Sobi
TiGenix NV announced that it has licensed the marketing and distribution of ChondroCelect, the cell-based medicinal product for the repair of cartilage defects of the knee to Swedish Orphan Biovitrum AB. [TiGenix NV] Download Press Release

Umbilical Cord Stem Cell Therapy Clinical Trial for Multiple Sclerosis Gets Green Light
Translational Biosciences, a subsidiary of Medistem Panama, has received the green light for a Phase I/II clinical trial using human umbilical cord-derived mesenchymal stem cells for multiple sclerosis from the Comité Nacional de Bioética de la Investigación Institutional Review Board in Panama. [Medistem Panama]
Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR^TM can help.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mesenchymal cell community.

Postdoctoral Fellow – Regenerative Medicine (University of California, San Francisco)

PhD Student – Stem Cell Biology and Replicative Senescence (RWTH Aachen University Medical School)

Postdoctoral Position – Cardiopulmonary Molecular Biology (Hannover Medical School)

Postdoctoral Associate – Cardiac Repair Mechanisms of Mesenchymal Stem Cells and Cardiac Stem Cells (University of Miami)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Cell Culture Specialist (Tisch MS Research Center of New York)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.